Explore the Agenda
7:30 am Check-In & Coffee
8:20 am Chair’s Opening Remarks
A Booming Radiopharmaceutical Landscape: Evaluating the Progress of TRPs in Europe & Beyond
8:30 am Radioligand Therapy: Successes & Future Challenges
Radiopharmaceuticals are on the rise worldwide. Join key players to explore how Europe is driving progress in this exciting field – and what it means for the future of cancer care around the world.
- Demonstrating significant progression-free survival benefits for mCRPC patients treated with Pluvicto
- The success of Pluvicto in improving progression-free survival compared to standard care
- New challenges and opportunities in RLT: new targets, combinations
9:00 am An Update on ProstACT Global: Comparing Standard of Care With or Without 177Lu-DOTA-Rosopatamab
- Evaluating the impact of adding 177Lu-DOTA-Rosopatamab to standard care in PSMA-positive mCRPC
- Assessing the safety and effectiveness of 177Lu-DOTA-Rosopatamab with androgen inhibitors or taxanes
- Exploring new therapeutic strategies for advanced prostate cancer using 177Lu-DOTA-Rosopatamab
9:30 am Delivering on the Promise of Targeted Radiopharmaceuticals: Emerging Therapy & Innovation Platforms
- Developing first-in-class versus best-in-class radiopharmaceuticals
- Emerging clinical data from best-in-class approaches
- Validation of preclinical platforms to deliver blockbuster after blockbuster
10:00 am Morning Break & Speed Networking
Discovery & Preclinical Track
Discovery & Preclinical Track
Lab Head, Molecular Imaging & RLT, Novartis AG
Chair: Josefine Reber, Lab Head, Molecular Imaging & RLT Novartis
Radioisotope Selection: Exploring Alpha VS Beta Emitters
11:00 am Elucidating Radiobiological Mechanisms of Cytotoxicity & Immune Modulation to Inform Selection of Optimal Radiopharmaceutical Targets
Director - Oncology Safety Sciences, AstraZeneca
- Investigating the cellular and molecular mechanisms underlying radiopharmaceutical-induced cell death to optimise therapeutic outcomes
- Exploring how radiopharmaceuticals interact with the immune system to enhance anti-tumour immunity and reduce resistance
- Leveraging insights from radiobiology and immune modulation to identify and select optimal radiopharmaceutical targets for improved tumour control and reduced toxicity
11:30 am Session Reserved for BIOEMTECH
12:00 pm Strategies for Targeted Isotope Delivery to Tumours
Vice President, Research, Y-mAbs Therapeutics Inc
- Exploring how different targeting strategies enhance selective isotope delivery to tumour sites
- Identifying key factors (e.g., half-life, energy emission, tissue penetration) for choosing the most effective isotopes for tumour treatment
- Assessing how optimal isotope selection improves tumour targeting, minimises off-target effects, and enhances therapeutic efficacy
Translational & Clinical Development Track
CMC & Sourcing Track
12:30 pm Lunch
Discovery & Preclinical Track
Exploring Targets Beyond PSMA: Ongoing Discovery to Find Real Hits on Novel Targets
1:30 pm Characterising Key Attributes of an Ideal Radiopharmaceutical Target for Alignment with Radiotherapeutic Properties
Chief Executive Officer & Chief Marketing Officer, Coretag
- Evaluating receptor expression profiles and proximity to radiosensitive tissues
- Defining target selection criteria based on emission characteristics of alpha versus. beta emitters
- Exploring strategies for stromal and internalising target engagement, including FAP-directed approaches
2:00 pm Session Reserved for Navigo Proteins
2:10 pm Towards Optimising Tumour Retention of FAP-Targeting Theranostics
CEO, ActiThera
- Discussing the promise of FAP as a target for the imaging and therapy of various solid tumours
- Summarising approaches used in the FAP field to optimise tumour AUC
- Exploring insights into Actithera’s approaches and molecules
Translational & Clinical Development Track
CMC & Sourcing Track
2:40 pm Afternoon Break & Poster Presentation Session
Investigating a Well-Rounded Approach to Isotope Selection from Discovery to Manufacturing
3:30 pm Lutetium 177 VS Terbium 161 – What are the Potentials for Next-Gen Radioisotopes?
- Evaluating the differences in emission profiles, half-lives, and tissue penetration between 177Lu and 161Tb
- Assessing the potential of 161Tb to enhance tumour cell kill through higher linear energy transfer and Auger electron emission
- Discussing production, labelling, and regulatory considerations for integrating 161Tb into next-generation radiopharmaceuticals
4:00 pm Optimising Isotope Selection for Scalable Radiopharmaceutical Commercialisation
- Evaluating isotope availability, production capacity, and logistics for reliable clinical and commercial use
- Aligning isotope half-life, emission type, and energy with therapeutic goals and pharmacokinetics
- Addressing regulatory, technical, and cost considerations for efficient scale-up and market readiness
4:30 pm Exploring Strategies for Improved Global Radio-Isotope & Therapy Supply Chain Management
- Investigating current challenges and solutions in global actinium-225 production and distribution
- Emerging technologies and infrastructure for scalable, high-purity isotope generation
- Addressing regulatory, logistical, and economic barriers to support widespread adoption of actinium-based therapies